INVESTIGATIONAL Preclinical‑stage. Not approved by FDA.

INVESTIGATIONAL Under development. Not cleared by FDA.

Latest

News & Milestones

Breakthroughs, publications, and company milestones from Seek Labs.

Press Release, Featured, Home Page

Featured

Seek Labs Maps 25/25 Viral Families through BioSeeker, Advancing a New Model for Sequence-Directed Antiviral Discovery

Seek Labs Maps 25/25 Viral Families through BioSeeker, Advancing a New Model for Sequence-Directed Antiviral Discovery The company’s comprehensive viral target atlas is designed to move development from reactive crisis response toward proactive, pre-identified genomic vulnerability mapping June 8, 2026 SALT LAKE CITY, UT (Business Wire) — Seek Labs, a private TechBio company building programmable…
Read article →: Seek Labs Maps 25/25 Viral Families through BioSeeker, Advancing a New Model for Sequence-Directed Antiviral Discovery

Press Releases

Official announcements and press releases from Seek Labs.

June 8, 2026

Seek Labs Maps 25/25 Viral Families through BioSeeker, Advancing a New Model for Sequence-Directed Antiviral Discovery

Seek Labs Maps 25/25 Viral Families through BioSeeker, Advancing a New Model for Sequence-Directed Antiviral Discovery The company’s comprehensive viral target atlas is designed to move development from reactive crisis response toward proactive, pre-identified genomic vulnerability mapping June 8, 2026 SALT LAKE CITY, UT (Business Wire) — Seek Labs, a private TechBio company building programmable…
May 7, 2026

Seek Labs Awarded U.S. Patent for Isothermal Molecular Amplification Chemistry Designed for Decentralized Testing

Seek Labs Awarded U.S. Patent for Isothermal Molecular Amplification Chemistry Designed for Decentralized Testing Newly issued patent covers foundational amplification chemistry designed to support sensitive molecular detection without thermal cycling or centralized laboratory infrastructure May 7, 2026 SALT LAKE CITY, UT (Business Wire) — Seek Labs, a private TechBio company building programmable platforms to decode,…
February 17, 2026

Seek Labs Awarded $2M USDA Grant for CRISPR Avian Flu Therapeutic

Seek Labs Awarded $2 Million Federal Grant for a Novel CRISPR-Based, Mutation-Resistant Therapeutic to Combat Avian Flu in Partnership with Canadian Food Inspection Agency USDA grant is part of a broader federal push to find innovative solutions to fight the highly infectious avian flu (HPAI), which continues to spread globally and impact egg and poultry…

Publications

The science behind the platform. Peer-reviewed and editorial publications from the Seek Labs team.

Home Page, Papers, Press Release

Dec 2025

Seek Labs Publishes Editorial Review on the Future of CRISPR Antivirals in an Era of AI-Designed Viral Threats

Seek Labs Publishes Editorial Review on the Future of CRISPR Antivirals in an Era of AI-Designed Viral Threats December 8, 2025 Read the full open-access review in Viruses Seek Labs today announced the publication of a new editorial review in Viruses (MDPI), authored by Alison O’Mahony, Senior VP of Research, and Douglas P. Gladue, VP…
Read publication →: Seek Labs Publishes Editorial Review on the Future of CRISPR Antivirals in an Era of AI-Designed Viral Threats
Papers, Press Release

Nov 2025

Seek Labs Publishes First Peer-Reviewed Paper Demonstrating A CRISPR-Based Therapeutic Is Effective Against African Swine Fever

Seek Labs Publishes First Peer-Reviewed Paper Demonstrating A CRISPR-Based Therapeutic Is Effective Against African Swine Fever November 17, 2025 SALT LAKE CITY, UT (Business Wire) – Seek Labs, a biotechnology company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the publication of a peer-reviewed paper in Viruses (MDPI),…
Read publication →: Seek Labs Publishes First Peer-Reviewed Paper Demonstrating A CRISPR-Based Therapeutic Is Effective Against African Swine Fever

From the team

Perspectives on programmable medicine, platform innovation, and the future of disease response.

Blog, Featured

Ebola Isn’t One Virus. We’ve Been Treating It Like One.

Ebola Isn’t One Virus. We’ve Been Treating It Like One. By Jared Bauer, CEO Ebola Bundibugyo (BDBV) is the strain driving the current outbreak in the Democratic Republic of the Congo and Uganda — and it is one the world is dangerously unprepared for. “No vaccine exists. No therapy exists. The virus circulated undetected for…

May 28, 2026
Blog, Featured, News

For Continuously Evolving Threats like Avian Influenza, We Must Design Durable Anti-Viral Therapeutics

For Continuously Evolving Threats like Avian Influenza, We Must Design Durable Anti-Viral Therapeutics Highly pathogenic avian influenza (HPAI) illustrates a clear and urgent application for Seek Labs’ platform based programmable therapeutic. By Dr. Douglas Gladue | March 11, 2026 Highly pathogenic avian influenza (HPAI) is a persistent and economically disruptive disease threat. It has been…

March 11, 2026
Blog, Featured, Home Page, News

Next Generation CRISPR: How Seek Labs’ Programmable Therapeutics Are Expanding the Promise of CRISPR-Powered Innovation

Next Generation CRISPR: How Seek Labs’ Programmable Therapeutics Are Expanding the Promise of CRISPR-Powered Innovation At Seek Labs, every day is World CRISPR Day. Our work in programmable therapeutics builds upon the same principles that make CRISPR so revolutionary: precision, adaptability, and speed. As we reflect on this transformative technology, we’re not just looking at…

October 23, 2025
Blog

We Can’t Feed the World If We Ignore Animal Disease: Why Veterinary Pathogens Are a Global Health Crisis

We Can’t Feed the World If We Ignore Animal Disease: Why Veterinary Pathogens Are a Global Health Crisis According to the WHO, 60% of emerging infectious diseases are zoonotic. And those risks are rising as deforestation and climate shifts push animals closer to humans. By Jared bauer, Ceo of Seek Labs | July 23, 2025…

July 23, 2025
Blog

RSV Isn’t Just a Cold — It’s a Global Crisis We Keep Ignoring

RSV Isn’t Just a Cold; It’s a Global Crisis We Keep Ignoring Why RSV is more dangerous than people think and what we’re doing to change that By Jared Bauer, CEO of Seek Labs | july 8, 2025 In January, my wife got sick. Really sick. RSV, influenza, and pneumonia, all at once. She’s a healthy,…

July 8, 2025
Blog

When Vaccines Aren’t Enough: Mapping Measles and Preparing for What’s Next

When Vaccines Aren’t Enough: Mapping Measles and Preparing for What’s Next Measles was supposed to be behind us. Instead, it’s back and it’s spreading. Jared Bauer, Ceo of Seek Labs | June 23, 2025 Consider a hypothetical but all-too-real scenario: In March 2025, Maria watched her son’s fever spike and rash worsen rapidly in their…

June 23, 2025

All news

Diagnostics, Featured, Home Page, News, Press Release

May 7, 2026

Seek Labs Awarded U.S. Patent for Isothermal Molecular Amplification Chemistry Designed for Decentralized Testing

Seek Labs Awarded U.S. Patent for Isothermal Molecular Amplification Chemistry Designed for Decentralized Testing Newly issued patent covers foundational amplification chemistry designed to support sensitive molecular detection without thermal cycling or centralized laboratory infrastructure May 7, 2026 SALT LAKE CITY, UT (Business Wire) — Seek Labs, a private TechBio company building programmable platforms to decode,…
Corporate, Featured, News

April 28, 2026

Dr. Alison O’Mahony Named 2026 Mentor of the Year

Dr. Alison O’Mahony Named 2026 Mentor of the Year by BioHive April 28, 2026 Dr. Alison O’Mahony, Senior Vice President of Research and Development at Seek Labs, has been named Mentor of the Year as part of BioHive’s 2026 Best of BioHive Awards. The award recognizes individuals who have made exceptional contributions to mentorship and…
Corporate, Featured, News

April 20, 2026

Jared Bauer Named Salt Lake City Titan 100 Honoree

Jared Bauer Named Salt Lake City Titan 100 2026 Honoree April 20, 2026 Jared Bauer, co-founder and CEO of Seek Labs, has been named a 2026 Salt Lake City Titan 100 honoree. The Titan 100 program recognizes the region’s top 100 CEOs and C-level executives, selected for their exceptional leadership, vision, and impact across industries.…
Corporate, Featured, Home Page, News

March 19, 2026

Seek Labs Joins BioMaP-Consortium to Support U.S. Biomanufacturing Preparedness Efforts

Seek Labs Joins BioMaP-Consortium to Support U.S. Biomanufacturing Preparedness Efforts As a member of the BioMaP-Consortium, Seek Labs gains access to a collaborative network advancing next-generation biomanufacturing and healthcare innovation. March 19, 2026 Seek Labs today announced that it has joined the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), a national public-private partnership focused on strengthening the…
Blog, Featured, News

March 11, 2026

For Continuously Evolving Threats like Avian Influenza, We Must Design Durable Anti-Viral Therapeutics

For Continuously Evolving Threats like Avian Influenza, We Must Design Durable Anti-Viral Therapeutics Highly pathogenic avian influenza (HPAI) illustrates a clear and urgent application for Seek Labs’ platform based programmable therapeutic. By Dr. Douglas Gladue | March 11, 2026 Highly pathogenic avian influenza (HPAI) is a persistent and economically disruptive disease threat. It has been…
Featured, Home Page, News, Press Release, Therapeutics

February 17, 2026

Seek Labs Awarded $2M USDA Grant for CRISPR Avian Flu Therapeutic

Seek Labs Awarded $2 Million Federal Grant for a Novel CRISPR-Based, Mutation-Resistant Therapeutic to Combat Avian Flu in Partnership with Canadian Food Inspection Agency USDA grant is part of a broader federal push to find innovative solutions to fight the highly infectious avian flu (HPAI), which continues to spread globally and impact egg and poultry…
Corporate, Featured, News

December 23, 2025

2025 Innovation & Impact Report
Home Page, News, Therapeutics

December 5, 2025

CRISPR Treatments for AI-Designed Synthetic Viruses: Rapid Programmable Countermeasures for Emerging and Engineered Viruses
Blog, Featured, Home Page, News

October 23, 2025

Next Generation CRISPR: How Seek Labs’ Programmable Therapeutics Are Expanding the Promise of CRISPR-Powered Innovation

Next Generation CRISPR: How Seek Labs’ Programmable Therapeutics Are Expanding the Promise of CRISPR-Powered Innovation At Seek Labs, every day is World CRISPR Day. Our work in programmable therapeutics builds upon the same principles that make CRISPR so revolutionary: precision, adaptability, and speed. As we reflect on this transformative technology, we’re not just looking at…

View all news →

Stay connected

Follow the work as it unfolds.

Stay connected to company milestones, scientific insights, and the work unfolding across BioSeeker, SAT, and Seek Diagnostics.